Hopec Pharma

Company Overview

Snapshot

Founded in February 2023 by Estee Rosen and Gadi Klarsfeld, Hopec Pharma operates with 1–10 employees. The company has raised $4 million across two funding rounds. In October 2025, Hopec Pharma was awarded a grant from the Israel Innovation Authority, marking a significant milestone in its development.

Business overview

Hopec Pharma is a Health Tech & Life Sciences company focused on transforming the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). The company develops HOPEC (UPEC-FimON), an innovative non-intravesical immunotherapy that utilizes a genetically modified Uropathogenic E. coli to trigger a targeted immune response. This technology aims to offer higher efficacy, fewer side effects, and a scalable, cost-effective alternative to current treatments. Hopec Pharma operates within the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, serving the healthcare and pharmaceutical industries globally, with a focus on markets such as China, North America, and Western Europe.

Company Intelligence Q&A

When was Hopec Pharma founded and by whom?

Hopec Pharma was founded in February 2023 by Estee Rosen and Gadi Klarsfeld.

What is Hopec Pharma's core product?

Hopec Pharma's core product is HOPEC (UPEC-FimON), an innovative non-intravesical immunotherapy designed for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).

What significant clinical milestones did Hopec Pharma achieve in 2025?

In 2025, Hopec Pharma produced its first GMP clinical batch (DOR-100), received Helsinki approval in July for Phase 1/a+b trials, signed clinical agreements with Hadassah and Sheba Medical Centers, and launched clinical trials in September.

Has Hopec Pharma received any grants?

Yes, in October 2025, Hopec Pharma was awarded a grant from the Israel Innovation Authority.

What is the total capital raised by Hopec Pharma?

Hopec Pharma has raised a total of $4 million across two funding rounds.